Evaluation of the Safety and Performance of SYMATESE AESTHETICS ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants in the Breast Augmentation

Last updated: June 24, 2024
Sponsor: Symatese Aesthetics
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

N/A

Treatment

ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants

Clinical Study ID

NCT05336526
CLIN PMI-004
  • Ages 18-65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to collect clinical data to evaluate the safety and performance of ESTYME® MATRIX Round microtextured breast implants in patients who receive these silicone gel-filled implants as part of their breast augmentation surgery in primary intention. This study also aims to measure patient and surgeon satisfaction.

An initial study of all ESTYME® MATRIX implants was conducted between 2018 and 2021. The purpose of the current EMMA study is to complete the data from this first study on a larger number of implants, and only on the ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants range for primary intention breast augmentation, with a view to obtaining marketing authorization (CE marking).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Aged between 18 and 65 years

  2. Eligible for bilateral breast augmentation in primary intention

  3. general breast enlargement for cosmetic purposes

  4. surgical correction of various congenital or acquired anomalies such asamastia, aplasia, hypomastia, hypoplasia, asymmetries*, Poland's syndrome*,ptosis ... * correction of asymmetries and Poland's Syndrome with concomitantaugmentation of the second breast (bilateral implantation)

  5. Signature of Patient Information Consent (PIC) & willingness to comply with theprotocol assessments and follow up visits

  6. Affiliation to the social security regime

Exclusion

Exclusion Criteria:

  1. Local or systemic infection or abscess anywhere in the body

  2. Existing carcinoma or pre-carcinoma of the breast with or without treatment

  3. History of subcutaneous mastectomy

  4. Subject with previous tissue expansion

  5. Diagnosis of active cancer of any type

  6. Pregnant subject or intending to become pregnant within three (3) months after theimplant procedure (women of childbearing potential must use effective contraceptionfrom 1 month before the implantation procedure until 3 months after the implantationprocedure)

  7. Has breastfed within three (3) months the implant surgery, or is still breastfeeding

  8. Tissue characteristics determined as clinically inadequate or unsuitable by thesurgeon (i.e. tissue damage resulting from radiation, inadequate tissue orcompromised vascularity, known wound healing complications)

  9. Has been previously implanted with a silicone implant or history of failurefollowing cosmetic augmentation

  10. History of autoimmune disease such as, but not limited to, lupus and scleroderma

  11. Any condition or treatment for any condition which, in the opinion of theinvestigator, may constitute an unwarranted surgical risk (e.g. severe lung orcardiac disease, unstable medical conditions, anaesthesia allergy, heavy smokers...)

  12. Anatomic or physiologic abnormality which could result to significant post-operativecomplications

  13. History of sensitivity to foreign materials or known allergy to any component of theESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implant

  14. Known alcohol abuse or history of alcohol abuse

  15. Psychological instability

  16. Underlying disease (HIV-positive, heart failure, renal insufficiency, diabetes,hypertension)

  17. Implanted metal or metal devices, history of claustrophobia, or other condition thatwould make a magnetic resonance imaging (MRI) scan prohibitive

  18. Unwilling to undergo any further surgery for revision

  19. Unrealistic/unreasonable expectations that entail a risk for the surgical procedure

  20. Participating in another clinical study or within exclusion period of a previousclinical study as determined by the investigator

  21. Has sociological, cultural or geographical factors which could interfere withevaluation or completion of the study

Study Design

Total Participants: 88
Treatment Group(s): 1
Primary Treatment: ESTYME® MATRIX Round Microtextured Silicone Gel-Filled Breast Implants
Phase:
Study Start date:
March 18, 2022
Estimated Completion Date:
September 30, 2025

Connect with a study center

  • Clinique Urbain V Elsan

    Avignon, 84000
    France

    Site Not Available

  • Clinique Saint George

    Nice, 06105
    France

    Site Not Available

  • Clinique Bizet

    Paris, 75016
    France

    Site Not Available

  • Clinique Sainte Geneviève

    Paris, 75014
    France

    Site Not Available

  • Clinique du Rond Point des Champs Elysées

    Paris, 75016
    France

    Site Not Available

  • Clinique Charcot

    Sainte-Foy-lès-Lyon, 69110
    France

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.